Plasmacytoid dendritic cell leukemia with potent antigen-presenting ability.
We report 2 patients with plasmacytoid dendritic cell leukemia (pDCL) expressing CD4, CD56, CD33, CD36, HLA-DR, CD123, CD86 and CD83 in the absence of lineage markers (myeloid, B, T or natural killer cells) except for CD33. Culturing leukemic blasts of both cases with IL-3 for 4 days increased the expression of surface molecules associated with antigen presentation, e.g. CD1a and CD40. Leukemic blasts of both cases possessed a considerable level of antigen-presenting ability to allogeneic lymphocytes in mixed leukocyte cultures. Culturing the blasts with IL-3 for 4 days markedly increased allogeneic antigen presenting ability. Combined with data showing evident graft-versus-leukemia effects without graft-versus-host disease in a cord blood stem cell transplanted pDCL case, leukemic cells in pDCL may act as potent antigen presenting cells in vivo, too.
Narita
Miwako
M
Laboratory of Hematology and Oncology, Graduate School of Health Sciences, Niigata University, Niigata, Japan. naritami@clg.niigata-u.ac.jp
Kuroha
Takashi
T
Watanabe
Norihiro
N
Hashimoto
Shigeo
S
Tsuchiyama
Junjiro
J
Tochiki
Nozomi
N
Saitoh
Anri
A
Satoh
Noriyuki
N
Furukawa
Tatsuo
T
Toba
Ken
K
Fuse
Ichiro
I
Aizawa
Yoshifusa
Y
Takahashi
Masuhiro
M
D000368:Aged; D017951:Antigen Presentation; D019070:Cell Lineage; D036101:Cord Blood Stem Cell Transplantation; D003713:Dendritic Cells / Q000276:immunology* / Q000473:pathology; D020544:Graft vs Leukemia Effect; D006801:Humans; D016130:Immunophenotyping; D007377:Interleukin-3 / Q000494:pharmacology; D007938:Leukemia / Q000276:immunology / Q000473:pathology* / Q000628:therapy; D008297:Male
D007377:Interleukin-3